Sign in
Taking people in United StatesEarly phase 1

Comparing two insomnia treatments in adults with short or normal sleep

Tests behavioral therapy and low-dose trazodone in adults with insomnia and short sleep.

Key facts

Who runs it
Milton S. Hershey Medical Center
Where
Denver, Hershey, and Pittsburgh, United StatesSee the 3 sitesAlso in 1 other country, 1 site
Trial code
Registry title
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia
Status
Recruiting
Phase
Early phase 1
People taking part
600 people, planned
Started
20 Mar 2024
Expected to end
31 May 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cognitive Behavioral Treatment for Insomnia (CBT-I)
  • Trazodone
  • Placebo
Record updated
10 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic insomnia. It compares a behavioral therapy (CBT-I) and low-dose trazodone, and looks at sleep and blood pressure.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Chronic insomnia. Body Mass Index (BMI) 18.5 kg/m2 or higher.
Earlier treatment
Cannot use other treatments for insomnia during the study. Cannot take sleep medicines more than 2 times per week. Cannot have started or changed sleep apnea treatment in the past three months.

Main reasons for not taking part

  • Lifetime psychotic or bipolar disorder
  • Untreated severe sleep apnea (AHI 15 or higher) or sleep apnea found by sleep study
  • Narcolepsy, hypersomnia or circadian rhythm disorder, including night shift work
  • Pregnant or breastfeeding, or planning pregnancy
  • Seated blood pressure above 180 (SBP) or 110 (DBP) mmHg, or EKG corrected QT interval 500 ms or more

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age 18 or older
  • Able to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site
  • Meets criteria for chronic insomnia
  • Body Mass Index (BMI) 18.5 kg/m2 and higher

Who cannot take part

  • History of severe apnea or an Apnea Hypopnea Index (AHI) ≥15 that is not currently treated with Positive Airway Pressure (PAP) therapy, an oral device or an implanted device, or was not treated with surgery or weight loss
  • Current use of prescription or over the counter medications taken for sleep greater than 2 times per week
  • Current use of systemic corticosteroids or opiate medications
  • Current use of medications contraindicated with trazodone
  • Life time diagnosis of psychotic or bipolar disorder
  • Meets criteria for narcolepsy or hypersomnia disorder
  • Meets criteria for circadian rhythm disorder (including night shift work)
  • Unstable medical conditions that would make participation unsafe or unfeasible
  • 2 hospitalizations or emergency room visits within past 12 months for chronic conditions
  • Active chemotherapy or radiation therapy for cancer
  • Lifetime diagnoses/treatment of chronic renal failure, hepatic insufficiency, chronic heart failure
  • Sleep apnea or periodic leg movement disorder as determined by sleep study
  • EKG corrected QT interval greater than or equal to 500 ms
  • Age < 18
  • Unable to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site
  • Unwilling to share email address/cell phone number to accept survey links
  • Started new or changed treatment for sleep apnea in the past three months
  • Does not meet criteria for chronic insomnia
  • Falls resulting in hospitalization, significant injury or fracture within past 12 months
  • Does not agree to refrain from other treatments for insomnia beyond what is offered in this study
  • BMI less than 18.5
  • Substance abuse or dependence in the past 12 months
  • Current pregnancy or breastfeeding; plans to get pregnant or unwillingness to use birth control for the length of the study
  • Blood Pressure levels defined as seated SBP greater than 180 or DBP greater than 110 mmHg

Where in United States

Also in 1 other country, 1 site

  • National Jewish HealthDenver, United StatesContact: Roxane HorbergTaking people
  • Penn State UniversityHershey, United StatesContact: Carrie CrileyTaking people
  • University of PittsburghPittsburgh, United StatesContact: Laurie BrarTaking people

About the trial

What the trial wants to find out

Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.

The 2 groups in the trial

  • Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with placeboPlacebo, for comparison

    Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received placebo for 8 weeks.

    Treatment: Cognitive Behavioral Treatment for Insomnia (CBT-I) and Placebo

  • Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with TrazodoneExisting treatment, for comparison

    Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received trazodone for 8 weeks.

    Treatment: Cognitive Behavioral Treatment for Insomnia (CBT-I) and Trazodone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial
Plain-language title
Comparing two insomnia treatments in adults with short or normal sleepGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 November 2025